trending Market Intelligence /marketintelligence/en/news-insights/trending/vVUuXvGg5A19bLJnCngTTg2 content esgSubNav
In This List

US FDA pushes Jazz narcolepsy drug review date to March 2019

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


US FDA pushes Jazz narcolepsy drug review date to March 2019

Ireland's Jazz Pharmaceuticals PLC said the U.S. Food and Drug Administration's review of its narcolepsy and sleep apnea drug has been extended with a new deadline of March 20, 2019.

The FDA's original deadline to complete the review of Jazz's solriamfetol was Dec. 20. Solriamfetol is designed to improve wakefulness and reduce excessive daytime sleepiness for adults with narcolepsy and sleep apnea.

Jazz submitted new material to the FDA during review discussions, and the regulator determined that the information would require major amendments to the drug's label, resulting in a longer timeline.

The Dublin-based company's top-selling drug, Xyrem, is another treatment for narcolepsy as well as cataplexy, and it brought in sales of $357.3 million in the third quarter.